The Dawn of Immunotherapy in Gastric and Colorectal Cancers
WebcastFaculty
OVERVIEW
The Dawn of Immunotherapy in Gastric and Colorectal Cancers is organized by prIME oncology Oncology and will be held during Mar 07, 2017 - Mar 07, 2018.
The target audience for this medical event is specifically designed to meet the needs of medical oncologists, radiation oncologists, and other healthcare professionals involved in the treatment of patients with gastrointestinal cancers. This CME Conference has been approved for a maximum of 1.5 AMA PRA Category 1 Credits.
Conference Objectives are :
Upon completion of this educational activity, participants should be able to:
• Describe the molecular basis for immunotherapy in cancers and the evidence supporting the theory that gastric and colorectal cancers are immunogenic
• Identify potential biomarkers of response to immunotherapy in gastric and colorectal cancers, with a focus on immune checkpoint inhibitors
• Assess new and emerging data supporting the efficacy of immunotherapy in colorectal cancer, the rationale for combining it with other agents, and important ongoing trials
• Evaluate the evidence for the use of immunotherapy in gastric cancer alone or in combination with other agents, and describe late-phase, ongoing clinical trials
• Contrast the unique aspects of monitoring response to immunotherapy and the unique potential treatment-emergent adverse events from immunotherapy with chemotherapy or targeted agents
Additional details will be posted as soon as they are available.
The target audience for this medical event is specifically designed to meet the needs of medical oncologists, radiation oncologists, and other healthcare professionals involved in the treatment of patients with gastrointestinal cancers. This CME Conference has been approved for a maximum of 1.5 AMA PRA Category 1 Credits.
Conference Objectives are :
Upon completion of this educational activity, participants should be able to:
• Describe the molecular basis for immunotherapy in cancers and the evidence supporting the theory that gastric and colorectal cancers are immunogenic
• Identify potential biomarkers of response to immunotherapy in gastric and colorectal cancers, with a focus on immune checkpoint inhibitors
• Assess new and emerging data supporting the efficacy of immunotherapy in colorectal cancer, the rationale for combining it with other agents, and important ongoing trials
• Evaluate the evidence for the use of immunotherapy in gastric cancer alone or in combination with other agents, and describe late-phase, ongoing clinical trials
• Contrast the unique aspects of monitoring response to immunotherapy and the unique potential treatment-emergent adverse events from immunotherapy with chemotherapy or targeted agents
Additional details will be posted as soon as they are available.
SPECIALITIES
OncologyGastroenterologyImmunotherapies
Quick Links